Board of Directors

Angiochem's Board of Directors is a distinguished group of industry leaders who oversee the activities of the company.

Dr. Jean-Paul Castaigne, M.D., MBA, President and CEO

Dr. Castaigne is a senior executive with extensive international experience in the pharmaceutical and biotech industry. Prior to joining Angiochem as CEO, he was COO and CSO of Conjuchem, and previously he was Vice President, Head of Global R&D at the Fournier Group in France. In addition, Dr. Castaigne spent eleven years with Novartis in a variety of management positions, including Corporate Vice President for Canada, President and Managing Director in the Philippines and Director of Medical and R&D in France. Dr. Castaigne has also worked with CILAG (J&J) and Sanofi in France. He received his MD from Paris University in 1975 and held the position of Associate Professor of oncology and pneumology in 1978. Dr. Castaigne received an MBA from HEC Paris in 1987. Dr. Castaigne is member of the board of the following biotech companies and organization: Tranzyme Pharma, Asmacure and BioQuebec.

Sena K. Biswas, Ph.D. Managing Director, Life Sciences, VIMAC Ventures

Dr. Biswas joined VIMAC as a Venture Partner in June of 2002 and became Managing Director, Life Sciences in January, 2003. Sena Biswas previously served as a Principal at TL Ventures, a leading national venture capital firm with over $1.4 billion under management. During his tenure as one of two life science investment professionals, TL Ventures invested in several early-stage life science companies that were later listed on the NASDAQ. Dr Biswas has served as Founding CEO or President of several life science companies, most recently at Merrimack Pharmaceuticals, a network biology-based, drug discovery company spun out of MIT and Harvard. His experience also includes Aventis Pharmaceuticals, where he was Director of Business Development and Bear, Stearns & Co. where he was an Associate in the Healthcare Investment Banking Group. Representing VIMAC, Dr. Biswas serves on the board of directors for Neotropix, Inc. Dr. Biswas received a PhD in Molecular and Cellular Biology from the University of Pennsylvania, an MBA from The Wharton School, and a BA in Biology from Brandeis University. He also completed a Research Fellowship in Molecular Immunology at Harvard Medical School.

Martin Godbout, O.C., Ph.D.

Dr. Godbout was the President and Chief Executive Officer of Genome Canada from April 2000 to October 2009, and before that he was Senior Vice President at BioCapital and President and General Manager of Société Innovatech Québec. Between 1996 and 2004, he was a member of the Board of the “Conseil de la Science et de la Technologie du Québec” and he has been an Advisory member of several Canadian biopharmaceutical venture firms such as SGF Santé, Société Innovatech du Grand Montréal and Royal Bank Ventures Inc. In 2005, Dr. Godbout was appointed Officer of the Order of Canada. He was also awarded the Grand Prix de Recherche from the Québec Foundation for Mental Disorders for his previous work on Alzheimer’s disease in 1991 and the “Prix Summa” in 1994 from the Faculty of Science and Engineering of Université Laval. In 1994, he also founded BioContact Québec which has become one of the most important biopharmaceutical symposiums in North America. He holds a B.Sc. in Biochemistry and a Ph.D. in Physiology and Molecular Endocrinology from Université Laval. In March 2006, Dr. Godbout was shortlisted by the editors of Nature Biotechnology, as one of twenty nominees who have made the most remarkable and influential contribution to biotech in the past ten years in the category “Biobusiness in the rest of the world.”

Jean-François Pariseau, M.Sc., MBA, Partner, Health Venture Fund, Business Development Bank of Canada

Jean-François Pariseau joined BDC Venture Capital in July 2001. He has over 15 years of investment and entrepreneurial experience in the life sciences sector. Prior to joining BDC, Mr. Pariseau was an investment manager at a venture capital fund with global investment activities in healthcare, information technology and advanced technologies; his duties included being responsible for healthcare investments in Canada and the United States. Over the past 12 years, he has invested and managed more than $200 million in biopharmaceutical and medical device companies in North America. Mr. Pariseau’s experience includes transactions in private and in public companies, IPOs, M&A and fund investments. Prior to this, he was CEO of a consulting company specializing in regulatory affairs as well as VP, R&D for a pharmaceutical-product distribution company, both of which he founded. Mr. Pariseau holds a Bachelor of Science in Biotechnology from Université de Sherbrooke, a Master of Science in Biomedical Sciences from Université de Montréal, and an MBA from HEC-Montréal. He currently sits on the Board of Directors of AngioChem Inc., Resonant Medical Inc., Osprey Pharmaceuticals USA and BioQuébec.